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Bovine herpesvirus 1 (BHV-1) infection is widespread and causes a variety of diseases. Although similar in
many respects to the human immune response to human herpesvirus 1, the differences in the bovine virus
proteins, immune system components and strategies, physiology, and lifestyle mean the bovine immune
response to BHV-1 is unique. The innate immune system initially responds to infection, and primes a balanced
adaptive immune response. Cell-mediated immunity, including cytotoxic T lymphocyte killing of infected
cells, is critical to recovery from infection. Humoral immunity, including neutralizing antibody and antibody-
dependent cell-mediated cytotoxicity, is important to prevention or control of (re-)infection. BHV-1 immune
evasion strategies include suppression of major histocompatibility complex presentation of viral antigen,
helper T-cell killing, and latency. Immune suppression caused by the virus potentiates secondary infections
and contributes to the costly bovine respiratory disease complex. Vaccination against BHV-1 is widely
practiced. The many vaccines reported include replicating and non-replicating, conventional and genetically
engineered, as well as marker and non-marker preparations. Current development focuses on delivery of
major BHV-1 glycoproteins to elicit a balanced, protective immune response, while excluding serologic
markers and virulence or other undesirable factors. In North America, vaccines are used to prevent or reduce
clinical signs, whereas in some European Union countries marker vaccines have been employed in the
eradication of BHV-1 disease.
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Abstract
Bovine herpesvirus 1 (BHV-1) infection is widespread and causes a variety of diseases.
Although similar in many respects to the human immune response to human herpesvirus 1,
the differences in the bovine virus proteins, immune system components and strategies,
physiology, and lifestyle mean the bovine immune response to BHV-1 is unique. The innate
immune system initially responds to infection, and primes a balanced adaptive immune
response. Cell-mediated immunity, including cytotoxic T lymphocyte killing of infected cells,
is critical to recovery from infection. Humoral immunity, including neutralizing antibody
and antibody-dependent cell-mediated cytotoxicity, is important to prevention or control of
(re-)infection. BHV-1 immune evasion strategies include suppression of major histocompat-
ibility complex presentation of viral antigen, helper T-cell killing, and latency. Immune
suppression caused by the virus potentiates secondary infections and contributes to the costly
bovine respiratory disease complex. Vaccination against BHV-1 is widely practiced. The many
vaccines reported include replicating and non-replicating, conventional and genetically
engineered, as well as marker and non-marker preparations. Current development focuses on
delivery of major BHV-1 glycoproteins to elicit a balanced, protective immune response, while
excluding serologic markers and virulence or other undesirable factors. In North America,
vaccines are used to prevent or reduce clinical signs, whereas in some European Union
countries marker vaccines have been employed in the eradication of BHV-1 disease.
Keywords: bovine herpesvirus 1 (BHV-1), adaptive immunity, vaccine, envelope
glycoprotein, differentiating infected from vaccinated animals (DIVA), immune suppression
1. Introduction
Bovine herpesvirus 1 (BHV-1) causes important diseases
of cattle globally (Gibbs and Rweyemamu, 1977; Beer,
2012). Infection and the resultant immunosuppression
contribute to the bovine respiratory disease complex
(BRDC), which has a large economic impact on the cattle
industry in USA (Jones and Chowdhury, 2007; Anon,
2011a).
The bovine immune response to infection is robust,
broad-based, and long-lasting, perhaps due to persistent
infection (Babiuk et al., 1996; Engels and Ackermann,
1996; Kaashoek et al., 1996a). The response begins with
internal and external signaling by infected cells, and pro-
ceeds through stimulation of innate and adaptive immune
cells, resulting in cytotoxic T lymphocyte (CTL) and virus
neutralizing (VN) antibody (Ab) to clear the infection and
prevent re-infection.
BHV-1 infection is commonly diagnosed serologically.
Serosurveys have been conducted in Africa (Straub, 1990;
El Hussein et al., 2005), South Asia (Nandi et al., 2009),
East Asia (Kampa et al., 2004; Yan et al., 2008), Australia
(St. George et al., 1967; Smith et al., 1995), North America
(Kahrs et al., 1964; Elazhary et al., 1984), South America
(Straub, 1990), and Europe (Wuyckhuise et al., 1994).*Corresponding author. E-mail: Randall.L.Levings@aphis.usda.gov
*c Cambridge University Press 2013 This is a work of the U.S. Government and is
not subject to copyright protection in the United States.
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Serological testing and removal of infected animals have
been successfully used to eliminate BHV-1 from Denmark,
Switzerland, and Austria (Ackermann and Engels, 2006).
BHV-1 disease is widely vaccinated against, on multiple
continents. A variety of vaccines have been employed,
such as replicating and non-replicating or conventional
and genetically engineered (Turin et al., 1999). Many of
the vaccines have had problems or issues in application,
including virulence, immunosuppression, recrudescence,
or failure to protect. In North America, the aim is disease
suppression, whereas in many EU countries vaccination is
used in eradication campaigns (van Drunen Littel-van den
Hurk, 2006). BHV-1’s large genome size has resulted in
investigation of its use as a viral vector for vaccination
against other cattle diseases (Kit et al., 1991; Schrijver
et al., 1997; Kweon et al., 1999).
The molecular characterization of BHV-1 and its
infection, and useful extrapolations from human alpha-
herpesvirus (aHV) infections, have led to the use of BHV-
1, as a model for vaccine and other technologies. The cost
and pervasiveness of BHV-1 disease and the mixed record
of vaccination success mean the knowledge gained
and tools developed from research and development are
likely to find practical and impactful application. For
these reasons, examination of the bovine immune re-
sponse to infection with and vaccination against BHV-1 is
important and relevant.
2. The bovine adaptive immune response to BHV-1
2.1 The mammalian and bovine immune response
to alphaherpesvirus infection
The bovine immune system is of interest because of the
economic importance of cattle to pastoral communities
and commercial enterprises globally. Its similarities to and
differences from the better-studied mouse and human
immune systems are only beginning to be understood.
Some features appear to be fundamental and are
conserved (Hirano et al., 2011), allowing useful general-
izations or extrapolations. However, there are also
differences in strategies [e.g., for generation of diversity
of lymphocyte (LC) antigen (Ag) receptors and immuno-
globulins (Igs)] between mammalian orders, families,
genera, and species. It has been noted that ‘cattle- specific
evolutionary breakpoint regions have a higher density of
species-specific variations in genes having to do with
lactation and immune responsiveness’ (The Bovine
Genome Sequencing and Analysis Consortium et al.,
2009). The interactions of stress, nutrition, and fertility
with the innate and adaptive immune systems are
important for cattle (Salak-Johnson and McGlone, 2007;
Lippolis, 2008).
Most of what is known about mammalian immunity to
aHV was first elucidated in the human herspesvirus 1
(HHV-1)-mouse system, and then confirmed or expanded
in HHV-1/2-human and other systems, e.g., suid herpes-
virus 1 (SHV1)-mouse or -swine. The bovine immune
response to BHV-1 has been well reviewed at intervals
(Rouse and Babiuk, 1978; Wyler et al., 1989; Tikoo et al.,
1995a; Babiuk et al., 1996; Engels and Ackermann, 1996;
Muylkens et al., 2007).
The response begins with internal and external
(cytokine) signaling by infected cells. Innate immune
cells including macrophages (Mf), polymorphonuclear
neutrophils (PMN), plasmacytoid dendritic cells (pDC),
and natural killer (NK) cells are recruited to the site
and activated. These immune cells secrete more cyto-
kines, kill virus-infected cells, and bridge to the adaptive
response, including by presenting Ag to LCs. It has been
noted that innate and adaptive immune cells have a
complex interaction in aHV infections (Schuster et al.,
2011).
Starting at day 5, and peaking days 7–10, helper T cells
activate Mf and NK cells, and promote the proliferation of
specific CTLs. Finally, beginning at day 10 and peaking
after the infection is largely resolved, VN and other Abs
are detectable. They likely help with clearing extracellular
virus and with cellular cytotoxicity. Ab can then protect
the host from reinfection (by recrudescence or another
exposure), and can protect the neonate via colostrum.
The main adaptive immune response to the virus and
virus-infected cells is to the viral envelope GPs: gB, gC,
and gD.
The bovine adaptive immune response to BHV-1 and
vaccination to prevent the diseases it causes are the foci of
this review. The BHV-1 life cycle and bovine innate
immune response to the virus are the subject of another
review (Levings and Roth, 2013).
2.2 Adaptive immune system components and
activities
The adaptive immune response is characterized by: (1) the
specificity of T- and B-LC receptors due to gene segment
rearrangement and assembly, mutation, and clonal
selection; and (2) the memory of the response (Bonilla
and Oettgen, 2010). B cells recognize surface epitopes
with the immunoglobulin B-cell receptor (BCR). T cells,
by means of the T-cell receptor (TCR), recognize peptides
that are the products of protein breakdown in another cell
and displayed on that cell’s surface in a complex with
a major histocompatibility complex (MHC) molecule
(Murphy et al., 2008). The adaptive response is commonly
described as having two ‘arms’, cell-mediated and
humoral, enabled by T-helper 1 and 2 responses, respec-
tively. The involvement of T cells in both ‘arms’ means
that, unlike the innate response, the adaptive response is
‘MHC-restricted.’
MHC restriction describes the phenomena of T cells
only being stimulated by peptides bound to ‘self’ MHC.
They only kill infected cells with the same MHC type I or
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proliferate when presented with Ag by cells of the same
MHC type II. This has been demonstrated in cattle using
multiple viral systems, including studies of genetic vari-
ation in strength and character of immune response to
pathogens, and determination of key amino acid (aa)
residues in MHC- binding pockets for vaccine design
(Collen and Morrison, 2000; Glass, 2004; Baxter et al.,
2009; Gerner et al., 2009; Glass et al., 2012).
However, for LCs to proliferate, become effector cells,
and generate memory cells, a ‘second signal’ beyond Ag
recognition by BCR or TCR is needed, such as binding by
a co-receptor and stimulation by cytokine. A third signal is
also proposed for efficient stimulation (Curtsinger et al.,
1999; Ruprecht and Lanzavecchia, 2006).
The bovine response to BHV-1 is balanced, including
generation of CTL and VN Ab. CTLs are considered im-
portant for virus clearing and recovery from an infection,
and Abs in the prevention of BHV-1 (re-)infection
(Babiuk et al., 1996).
2.2.1. Antigen presenting cells
Dendritic cells (DCs), Mfs, and B cells can serve as
antigen presenting cells (APC), because in addition to
presenting Ag peptides on MHC I or II, when activated
during an infection they express the co-stimulatory mol-
ecules needed to activate T cells (Renjifo et al., 1999;
Murphy et al., 2008). They migrate to the local draining
lymph node to do so. DCs have the unique ability to
sensitize (prime) nai¨ve T cells. Mfs and B cells present
engulfed and soluble Ag, respectively, to primed effector
T cells (Murphy et al., 2008).
Conventional DCs (cDCs) are so named to differentiate
them from pDC, which have a different origin and dis-
tribution in tissues. cDCs, also known as myeloid DCs,
include migratory cells and lymphoid-resident cells (Freer
and Matteucci, 2009). cDC: (1) have specialized mech-
anisms for Ag capture and processing; (2) migrate to
defined sites in lymphoid organs to initiate immunity;
and (3) rapidly mature in response to a variety of
microbial and other stimuli (e.g., cytokines produced by
innate immune cells) (Steinman and Hemmi, 2006). After
activation, cDC produce interleukin (IL)-12 and IL-15
that stimulate interferon (IFN)-g secretion by NK cells,
and promote differentiation of CD4+ and CD8+ T cells
(Lambotin et al., 2010). So, they serve as a major link
between innate and adaptive immunity. cDCs are con-
tinuously produced and positioned at the skin, mucosal
surfaces, and in the blood, so they are likely to rapidly
encounter and be activated by invading pathogens
(Murphy et al., 2008). cDCs can be infected by viruses
themselves, can phagocytize infected cells, or can micro-
pinocytose Ag. Migrating cDC may also transfer Ag to
lymph node resident DC (Murphy et al., 2008; Singh and
Cresswell, 2010).
cDCs are equipped with a set of varied pathogen
recognition receptors (PRR), such as toll-like receptors
(TLR) in the endosome and retinoic acid-inducible gene I
(RIG-I)-like receptors (RLR) in the cytosol. Damage-
associated molecular patterns (DAMP) may also activate
immature DC (Nace et al., 2012). Stimulation changes the
chemokine receptors on the cDC, which in turn results in
their ability to migrate to the peripheral lymphoid tissue
to activate nai¨ve T cells (Murphy et al., 2008). Activated
DCs also present many peptide-MHC complexes and
co-stimulatory molecules, such as B7.1 (CD80) or B7.2
(CD86), for which T-cells express complementary CDs
(e.g., CD28) (Murphy et al., 2008).
cDCs comprise two main subsets: CD8, which
are efficient at presenting exogenous Ag on MHC II to
CD4+ T cells; and CD8+, which present Ag on MHC I
to CD8+ T cells (Reizis et al., 2011). Presentation to nai¨ve
CD8+ T cells is known as cross-priming, and presentation
to stimulated ones is known as cross-presentation (Singh
and Cresswell, 2010). Cross-presentation is important
for the response to viruses that do not infect APCs
directly. The dominant mechanism for cross-presentation
is translocation of Ags to the cytosol, where proteasomal
degradation generates peptides, which are then trans-
ported via the transporter associated with antigen
processing (TAP) and bind to newly synthesized MHC I
(Singh and Cresswell, 2010). DC can also regulate T cell
differentiation with IL (Freer and Matteucci, 2009). cDCs
produce IL-6, IL-8, IL-12, and tumor necrosis factor (TNF)-
a (Murphy et al., 2008). DCs performed better than
monocytes as APCs for BHV-1 (measured by stimulation
of T-cell proliferation in vitro). The DCs were not BHV-1-
infected (Renjifo et al., 1999).
Mfs from BHV-1-infected cattle were shown to express
increased levels of MHC II (Tikoo et al., 1995a), and Ag
presentation by bovine alveolar Mfs was shown to
stimulate proliferation of T cells in vitro. Bovine alveolar
Mf and monocytes are permissive to BHV-1 infection
(Renjifo et al., 1999), resulting in the impairments de-
scribed in another review focused on the innate immune
system (Levings and Roth, 2013).
B cells can internalize Ag bound to the BCR, and
process it in the endosome (triggering TL7 and TLR9, a
third signal for the B cells), leading to presentation of Ag
on MHC II (Lanzavecchia and Sallusto, 2007).
2.2.2. Lymphocytes
LCs are the effector cells of the adaptive immune system.
Study of leukocyte differentiation molecules has shown
that many of those identified in human beings and mice
(e.g., CD-2, 3, 4, 8) are highly conserved in structure
and function across mammalian species (Davis and
Hamilton, 1998).
2.2.3. T lymphocytes
T-cell receptors are constituted of two chains, each of
which is coded by recombined gene segments (resulting
in high diversity). The gene segments are variable (V),
junction (J), diversity (D), and constant (C). The proteins
are made by recombination of VJC (a and g chains) and
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VDJC (b and d chains) genes (Murphy et al., 2008).
Nucleotide deletion and substitution at the V(D)J junction
by exonuclease and terminal deoxynucleotide transferase
activity increases the diversity achieved during recombi-
nation. Consequentially much of the variability is focused
in the complementarity determining region (CDR) 3,
encoded by the V(D)J junction (Connelley et al., 2008).
The CDR3s of both chains are central in the binding site
and key to Ag recognition (Murphy et al., 2008).
Human and murine TCRs are predominantly ab .
There are 40–70 variable a or b gene segments, many J
segments, and the D gene for the b chain is frequently
read in three frames. The pairing, recombination, and
junctional diversity together lead to a diversity of 1018
(Murphy et al., 2008). The contribution of g d TCR to TCR
diversity in humans is minimal.
For cattle it was assumed that the high levels of g d
diversity observed meant ab diversity was likely to be
low, but this appears not to be the case. Over 400 genes
have been observed in the ad locus (Reinink and Van
Rhijn, 2009) and 48 functional Vb genes of 17 subfamilies
were identified. Clonal expansions were distributed over
a large number of Vb subfamilies, although a limited num-
ber of clonotypes dominated the response (Connelley
et al., 2008).
2.2.4. Bovine gd T cells
Unlike in human beings and mice, g d T cells are a major
population of T cells in cattle, particularly in calves,
where they account for 60% of peripheral blood
leucocytes (PBLs) (Chen et al., 2009). There is more gene
diversity (VDJC g ; VJC d ) in ruminants and some other
species than in mice and humans (Reinink and Van Rhijn,
2009), and multiple g genes are used (Guzman et al.,
2012). g dTCRs interact with non-classical MHCs in mice
and humans; it is believed unlikely that g dTCR interact
with classical MHC in cattle (Reinick and Van Rhijn, 2009).
Two populations of g d T cells have been found
(MacHugh et al., 1997): WC1+, CD2, CD4, CD8; and
WC1, CD2+, CD8+/. WC1+, CD2, CD4, CD8 cells are
present in peripheral blood, marginal zones of the spleen,
dermal, and epidermal layers of the skin and lamina
propria of the gut. The majority of WC1, CD2+ CD8+/
cells is localized in the red pulp of the spleen. The two
populations use different families of TCR genes
(MacHugh et al., 1997; Blumerman et al., 2006). Up to
90% of g d T cells in PBL are WC1+ (Baldwin et al., 2000).
WC1+ g d T cells are believed to be inflammatory, and
WC1 g d T cells regulatory (Meissner et al., 2003; Chen
et al., 2009).
WC1 is a transmembrane glycoprotein encoded by a
large, multi-gene family, part of the group B scavenger
receptor cysteine-rich (SRCR) superfamily (Herzig and
Baldwin, 2009; Herzig et al., 2010). Its function is un-
known but may serve as a functional homolog of CD4 and
CD8 on ab T cells, regulating g d T-cell response or
affecting signaling from outside the cell (Chen et al.,
2009). Isoforms WC1.1 and WC1.2 have been identified.
The largely non-overlapping populations of g d T cells
bearing them decrease with age differently and appear to
have distinct immunological roles (Rogers et al., 2005).
Pathogen-associated molecular patterns (PAMPs) prime
bovine g d T cells, as observed by an increase in receptors
in the absence of IFN-g secretion (Jutila et al., 2008). A
population of WC1+ g d T cells increased expression of
MHC II, processed Ag, and demonstrated NK cell-like
killing in response to infection with foot-and-mouth
disease virus (FMDV) (Toka et al., 2011). A large popu-
lation of CD8+ T cells in cattle is g d T cells (MacHugh
et al., 1997), and a subset of CD8+ g dT cells home to
mucosal tissues due to selective expression of adhesion
molecules and chemokine receptors (Wilson et al., 2002).
A population of peripheral blood g d T cells increased
rapidly upon inoculation with or exposure to BHV-1
(Amadori et al., 1995). Vaccination with one dose of
modified live BHV-1 generated g d T cells in the peri-
pheral blood of cattle that became activated in response
to live BHV-1 in culture (using CD25 as a marker)
(Endsley et al., 2002). Of two populations of bovine g d T
cells studied (CD2 and CD2+), one (CD2/D62L+) was
reduced after vaccination with product containing inacti-
vated BHV-1 and other viruses (Vesosky et al., 2003).
2.2.5. CD8, CD4 and T-cell types
Double-positive thymocytes that have been positively
selected develop into either CD4+ or CD8+ T cells, as
determined by the MHC-restriction specificity of their TCR
(Singer et al., 2008). CD8+ cells become CTLs. CD4+ cells
can differentiate into T-helper 1 (Th1), T-helper 2 (Th2),
T-helper 17 (Th17) or T regulatory (Treg) cells (Murphy
et al., 2008). IL-12, IL-18, TNF-a and IFN-a are associated
with skewing nai¨ve T cells to Th1. Th2 cells are produced
in the absence of such cytokines and in the presence
of IL-19. Transforming growth factor (TGF)-b promotes
the generation of Treg cells, whereas IL-6 inhibits
the generation of Treg and induces Th17 cells (Freer and
Matteucci, 2009). Th1 cells activate Mfs, including
increasing their ability to kill intracellular pathogens
(such as BHV-1). Th2 cells provide help in B-cell acti-
vation and class switching. Th17 cells enhance neutrophil
response, and Treg cells suppress the T cell response
(Murphy et al., 2008).
IFN-g is produced by Th1 CD4+ and CD8+ CTL
effector T cells as part of the adaptive immune response
(Schoenborn and Wilson, 2007). IL-12 produced by APC
stimulates T cells to produce IFN-g (Jaime-Ramirez et al.,
2011). It is ‘a predominant response after BHV-1 infection’
(Campos et al., 1989) and is necessary for the activation of
non-MHC restricted cytotoxic activities mediated by Mf.
Bovine CTLs (Hogg et al., 2011), Th1s, and Th2s have
been characterized. Although a strict Th1/Th2 dichotomy
was not observed, a biased immune response was indi-
cated when the cytokines expressed by cloned Th cells
with different Ag specificities were compared
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(Brown et al., 1998). There is evidence for bovine Treg
activity in populations of CD4+, CD25+ and of WC1+,
CD4+, CD25+ g d T cells (Coussens et al., 2012).
2.2.6. CD8 T cells
CD8+ T cells predominantly recognize peptide–MHC I
complexes (because CD8 binds best to MHC I), and kill
the cells that bear them. The peptides are bound primarily
at the ends of the MHC binding groove. MHC I is present
on all cells and are normally loaded with self-peptide frag-
ments generated by proteasomes via TAP (Murphy et al.,
2008). Typically, viral proteins are processed into pep-
tides in the cytoplasm by proteasomes. They bind to the
TAP1-TAP2 heterodimer, and after the dimer undergoes
conformational changes, are transported into the endo-
plasmic reticulum lumen where they are loaded onto
MHC I molecules (Neefjes et al., 1993; Knittler et al.,
1999). The MHC I–peptide complexes are presented on
infected cell or APC surfaces. IL-12 and IFN-I have been
proposed as the third signal for human CD8 (Curtsinger
et al., 1999; Curtsinger and Mescher, 2010).
CTLs kill by releasing perforin, which helps deliver
granzymes into the target cell, granzymes, which are pro-
proteases that are activated intracellularly to trigger apo-
ptosis in the target cell, and granulysin (in human beings).
CTLs also carry the membrane-bound effector molecule
Fas ligand (CD178), which binds to Fas (CD95) on a target
cell to activate apoptosis in the Fas-bearing cell. This latter
mechanism may be less important for virus-infected
cell killing than for killing LC after the response is over
(Murphy et al., 2008).
Granzymes trigger apoptosis by activating caspases. For
example, granzyme B cleaves and activates caspase 3,
which triggers a cascade ending in DNAse. The DNAse
degrades both cellular and viral DNA. Granzyme B also
triggers apoptosis through actions that result in the release
of apoptosis-inducing molecules, including cytochrome c
(Murphy et al., 2008). Bovine CD8+ T cells express per-
forin (increasing with age) (Hogg et al., 2011) and have
demonstrated MHC I-restricted killing in vitro (Guzman
et al., 2008).
BHV-1-encoded proteins appear on the cell surface to
serve as targets within 3–4 h after infection (Babiuk et al.,
1975, 1996). gC and gD were demonstrated targets for
CD8+ CTL (Denis et al., 1993), although when cells were
infected with vaccinia expressing BHV-1 gB, gC, or gD,
memory T-cell populations did not react with them (Hart
et al., 2011). Bovine CTL killing was MHC I-restricted
and BHV-1-specific (Splitter et al., 1988; Hart et al.,
2011). Cell-mediated immunity (CMI) responses peaked
7–10 days after infection and correlated with recovery
(Babiuk et al., 1996). CTLs likely play a role in control
of recrudescence from latency in aHVs (Jones and
Chowdhury, 2007).
Herpesviruses (HV) have multiple mechanisms to
evade CTL killing (Ploegh, 1998), and in some cases
even closely related viruses such as aHV use different
molecules for the same mechanism, or different mechan-
isms for the same molecule (Koppers-Lalic et al., 2008;
Deruelle and Favoreel, 2011). It should be noted that
although in BHV-1 infection CD4+ T cells are killed pref-
erentially, CD8+ numbers decreased in PBMC in infection,
resulting in decreased CMI (Winkler et al., 1999).
The BHV-1 gN homolog encoded by UL49.5 (Liang
et al., 1993) interferes with peptide transport for MHC
loading (Hinkley et al., 1998). It binds to TAP, inhibits
its peptide transport, and results in TAP degradation
(Koppers-Lalic et al., 2005; Lipin´ska et al., 2006). The
BHV-1 UL49.5 protein is predicted to be composed of an
N-terminal 22 aa signal sequence, a luminal 32 aa domain,
a 25 aa transmembrane domain, and a 17 aa cytoplasmic
tail (Liang et al., 1993; Lipin´ska et al., 2006). UL49.5 binds
TAP via its transmembrane domain and inhibits TAP
conformational transitions (Loch et al., 2008; Verweij
et al., 2008). Deletion of the entire cytoplasmic tail or the
terminal two aa of UL49.5 eliminates TAP degradation
(Loch et al., 2008), and it was determined that a 3-aa
luminal sequence signals the aa in the cytoplasmic tail
to initiate both inhibition and degradation of TAP (Wei
et al., 2011). Infection with BHV-1 with deletions in both
luminal and terminal sequences induced more rapid
onset (but similar peak levels) of VN Ab and CMI in calves
than infections with wild-type BHV-1 (Wei et al., 2012).
The suppression of MHC I Ag presentation results in BHV-
1 immune evasion in the initial stages of infection
(Koppers-Lalic et al., 2001, 2005, 2008; Gopinath et al.,
2002), which is consistent with the previously observed
transient suppression of CMI early in infection (Ohmann
and Babiuk, 1985; Tikoo et al., 1995a). It is of interest that
the gN homologs of various varicelloviruses employ di-
verse mechanisms to interfere with TAP activity (Koppers-
Lalic, 2007; Deruelle and Favoreel, 2011).
Other BHV-1 factors inhibit CTL killing. BHV-1 gG is a
chemokine-binding protein that prevents homing of LCs
to sites of infection (Jones and Chowdhury, 2007). BHV-1
viral host shutoff (VHS) protein shuts down synthesis of
MHC I (and MHC II), reducing Ag presentation (Koppers-
Lalic et al., 2001; Gopinath et al., 2002; Muylkens et al.,
2007). The latency-related (LR) alternate transcript binds
BH3-interacting domain death agonist (Bid), which is
specifically cleaved by granzyme B. In this way LR pro-
teins impair the CTL-induced death of infected neurons
(Jones and Chowdhury, 2007).
Other aHV immune evasion activities may be assumed
for BHV-1, but have not yet been demonstrated. Despite
low aa sequence similarity, the US3 homologs show
‘substantial functional conservation’ (Deruelle and Favor-
eel, 2011). HHV-1 US3 has multiple immune evasion
activities, and many of these have also been observed
in SHV1. US3 interferes with: (1) fas-mediated apoptosis;
(2) MHC I presentation of Ag, as do the homologs HHV3
open reading frame (ORF) 66 and SHV1 US3; and
(3) endocytosis of gB in HHV-1, which has not been
shown for BHV-1 (Deruelle and Favoreel, 2011).
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The HHV3 US3 homolog ORF66 retains mature MHC I
complexes in the cis/medial Golgi (Griffin et al., 2010).
HHV-1 gD also blocks apoptosis (Roizman and Taddeo,
2007).
In other cases, aHV anti-CTL or anti-apoptosis factors
have no homolog in BHV-1. HHV-1 gJ blocks CTL
(Roizman and Taddeo, 2007), but has no homolog in
BHV-1 (Schwyzer and Ackermann, 1996; Schmitt and
Keil, 1998). HHV-1 infected cell protein (ICP) 47 (IE12)
inhibits MHC I expression (Bauer and Tampe´, 2002), but
has no homolog in BHV-1 (Ambagala et al., 2004). Finally,
HHV-1 US11-encoded proteins including ICP 34.5 interact
with protein kinase R (PKR) and Beclin 1, both inhibiting
autophagy and presentation of GPs on the cell surface
(Shah et al., 2009; Cavignac and Esclatine, 2010; Taylor
et al., 2011), but there are no homologs in BHV-1
(Schwyzer and Ackermann, 1996; Schmitt and Keil, 1998;
Henderson et al., 2005).
BHV-1 infection leads to programmed cell death, with
p53 and caspases activated (Devireddy and Jones, 1999).
Penetration of the cell is not needed (Hanon et al., 1999).
The induction or blocking of apoptosis is a matter of
timing for the host and aHV (Srikumaran et al., 2007).
Early in the cell infection, apoptosis destroys viral com-
ponents (including progeny DNA), obviating their assem-
bly and release. Thus, when danger signals and immune
cells induce apoptosis, there is an advantage to the host.
After assembly, however, apoptosis may be advantageous
to release of the virus (Nguyen and Blaho, 2009). The
balance may also be cell type dependent.
2.2.7. CD4+ T cells
CD4+ T cells predominantly recognize peptide–MHC II
complexes (because CD4 binds best to MHC II) and are
activated by or activate the cells that bear them. MHC II are
borne primarily by APC, and bind proteasome-degraded
peptides along their length (Murphy et al., 2008). IL-1
has been proposed as the third signal for human CD4
(Curtsinger et al., 1999; Curtsinger and Mescher, 2010).
CD4+ Th1 can bear Fas ligand, which triggers death of
the Fas-bearing cell (Murphy et al., 2008).
During BHV-1 infection, CD4+ T cells are considered to
be essential for virus clearance in vivo. CD4 T cells, but
not g d T cells or CD8+ T cells, were identified as the
limiting cell type in Ag-induced proliferation in BHV-1
infection (Denis et al., 1994). They are required for the
generation of Ab-producing cells, MHC II-restricted CD4+
CTL (Wang and Splitter, 1998), and other cytotoxicity
activity (Renjifo et al., 1999). Th1s secrete IL-2, IL-12, IFN-
g and Th2s secrete IL-4, IL-5, IL-6 and IL-10 to drive the
Ab response (Campos et al., 1994). CD4+ T cells were
cytotoxic against Mfs pulsed with BHV-1 peptides, acting
through Fas and in an MHC II-restricted fashion (Wang
and Splitter, 1998). The association of BHV-1 Ab response
and MHC II genotype has been studied (Juliarena et al.,
2009).
BHV-1 gB, gC, gD, and viral protein (VP) 8 are
recognized by CD4 T helper cells from immune cattle
(Hutchings et al., 1990; Leary and Splitter, 1990). gE, gI,
and gG were shown not to be significant for lymphopro-
liferative responses (Denis et al., 1996). T-cell hetero-
hybridomas specific for gB, gC, and gD have been
generated (Nataraj and Srikumaran, 1994), and T-cell
epitopes have been mapped on BHV-1 gB (Gao et al.,
1999) and gD (Tikoo et al., 1995b).
BHV-1 infects and results in apoptosis of CD4+ T cells,
including activated ones (Griebel et al., 1990; Eskra and
Splitter, 1997; Winkler et al., 1999). CD4+ but not CD8+
T cells were shown to be infected, and gD (g 1, leaky-late)
but not gC (g 2, late) transcripts were detected, indicating
a non-productive infection (Winkler et al., 1999). UV-
irradiated BHV-1 suppressed IL-2 and (heterologous) Ag-
induced proliferative responses (Hutchings et al., 1990).
Anti-gB or gD Ab was able to block this effect. BHV-1 has
other mechanisms of reducing CD4+ T-cell responses.
BHV-1 VHS (UL41) causes a decrease of MHC II (and
MHC I) presentation (Muylkens et al., 2007). Light (L)-
particles (Dargan et al., 1995) have been observed in
BHV-1 infected MDBK cells and are believed to be
involved in immune evasion (Meckes and Raab-Traub,
2011). They do this by shuttling HLA-DR (MHC II) to the
exosomal secretion pathway instead of the cell surface.
2.2.8. B lymphocytes
Naive B-cell activation is dependent on three signals:
(1) BCR binding by Ag, followed by (2) cognate inter-
action with helper T cells through an immunological
synapse, and (3) TLR stimulation (Ruprecht and
Lanzavecchia, 2006; Lanzavecchia and Sallusto, 2007;
Murphy et al., 2008). The B-cell ‘co-receptor complex’
includes CD21 [C receptor 2 (CR2)], CD19, and CD81. If
the cleaved C fragment C3d is bound to Ag, the com-
plement can bind CR2, the Ag can bind BCR, and the
complex of the two can result in augmented signal
(Murphy et al., 2008). Some repeating Ags (T-cell
independent Ag) and anti-idiotypic Ab are able to provide
multiple signals by cross-linking BCR.
BCR binding up-regulates TLRs (Ruprecht and Lanza-
vecchia, 2006) and MHC II (Ratcliffe and Mitchison, 1984),
which are keys to subsequent signals. Specific activation
of the B cell by its cognate T cell (a helper T cell primed
by the ‘same’ Ag) consists of ILs and ligand (T-cell CD40L
to bind B-cell CD40) (Murphy et al., 2008). The T cells
must recognize Ag on the B cell in association with
MHC (Ratcliffe and Mitchison, 1984). The T-cell – B-cell
immunological synapse is enriched in the center for TCR–
MHC–peptide and CD40-CD40L, and ‘sealed’ at the
periphery by interaction of T-cell LFA-1 and B-cell
ICAM-1 (Murphy et al., 2008). The T and B cells polarize
their secretory and endocytic/exocytic machinery, respec-
tively, toward the synapse (Duchez et al., 2011). Th2s
provide help in B-cell activation and secrete the B-cell
growth factors IL-4, IL-5, IL-9, and IL-13. In cattle, IL-2 was
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observed to drive the Ab response, but other factors may
drive it to one class or another (e.g., IgG1 with IL-4 or
IgG2 with IFN-g ) (Estes and Brown, 2002; Estes, 2010).
The roles of cytokines in the mouse were not found to
extrapolate well to cattle.
2.2.9. Immunoglobulins
Ig generation, classes and subclasses, and strategies
for their use may vary between mammalian species. For
example, the ileal Peyer’s patch is a likely bursa equi-
valent in cattle (Meyer et al., 1997). The concentration of
different Ig classes in milk and colostrum varies consider-
ably according to species, breed, age, stage of lactation,
and health status. In many species, absorption of Igs is
selective and receptor mediated. In ruminants, absorption
is non-selective during the first 12–36 h after parturition
(Marnila and Korhonen, 2011). Ig subclasses do not match
between species because the species diverged before the
classes or subclasses subdivided (Butler, 1995). IgG1 is
the primary secretory Ig in cattle.
Diversity of Ag specificity is generated by five main
mechanisms: (1) combinations of different variable-light
(VL) and -heavy (VH) domains; (2) combinations of differ-
ent V, diversity (D), and J genes; (3) addition and deletion
of nucleotides at junctions of V, (D), and J genes during
recombination; (4) somatic hypermutation; and (5) gene
conversion. Different species have been found to
use different strategies to generate diversity (reviewed
in Butler, 1997). Primates and rodents express a large
number of V, D, and J genes and emphasize com-
binatorial mechanisms as well as templated (Ag-driven)
somatic hypermutation (mutations in ‘hotspots’ while
the B-lymphocyte is in the germinal center) (Teng and
Papavasiliou, 2007). Artiodactyls, lagomorphs, and
chickens, conversely, express few V, D, and J genes and
emphasize untemplated somatic mutation and gene
conversion.
Bovine Ig genes (C, then V, then J and D) were located
on chromosomes (Zimin et al., 2009), using homology to
mouse and human genes and the identification of flank-
ing, conserved recombination signal sequences (RSS)
(reviewed in Butler, 1995, 1997). It was determined that
cattle express one VH family (Saini et al., 1997; Niku et al.,
2012). Bovine light (L) chains are predominantly lambda
type, with only a few sub-families of genes, and only a
few sub-sub-families are used (Sinclair et al., 1995). One
J gene is predominantly expressed in each of H (Saini
et al., 1997; Zhao et al., 2003) and L (Pasman et al., 2010)
chains. Three D genes have been identified, with varying
lengths that contribute to varying length H chain CDR3,
including the extremely long ones found in IgM only
(Shojaei et al., 2003).
Ig effector function is in the crystallizable fragment (Fc),
or C domains. Key Ig effector functions in the immune
response to BHV-1 include VN, C fixation, and Ab-
dependent cell-mediated cytotoxicity (ADCC). These
functions are important late in the immune response,
and protect the host from further primary or later re-
infection. They are effective against virions and infected
cells.
2.2.10. Virus neutralization by Ab
Ab neutralization of animal virus infectivity can occur by
multiple mechanisms (Klasse and Sattentau, 2002; Read-
ing and Dimmock, 2007). Extracellular Ab may (1)
aggregate virions and reduce the number of infectious
centers, (2) mimic a cell receptor to bind virions and lead
to premature virion steps (e.g., release of the genome),
(3) inhibit virion attachment by blocking receptor en-
gagement, (4) inhibit fusion, either at the cell membrane
or in an endocytotic vesicle, or (5) bind to a cell-surface
protein and result in the transduction of a signal into the
cell that aborts the infection. Post-entry neutralization
can occur by transmission of a signal via the virus surface
protein to the virion core. Transcytosing IgA may
neutralize virus when their respective vesicles fuse. Ab
may bind nascent virions and block their budding or
release from the cell surface (Reading and Dimmock,
2007).
In the bovine immune response to BHV-1, Ab is the key
to binding GPs and preventing attachment. This can occur
to prevent extracellular virus from infecting host cells late
in primary infection, during re-activation, and upon
secondary exposure. Ab can coat the virus as it is being
shed (Pastoret et al., 1979).
In the primary response, gB, gC, and gD are the
primary inducers and targets of neutralizing Ab (Turin
et al., 1999). The response is expanded in recrudescence
or secondary exposure – it is elevated against the major
GPs, and responses to minor GPs like gE ‘become detec-
table.’ Dubuisson et al. (1992) examined the neutraliza-
tion mechanisms of monoclonal Ab (MAb) to gB, gC, and
gD. The majority of MAbs did not prevent attachment.
Few MAbs to gB were effective. Anti-gD MAb worked as
well after attachment as before, which was likely due to
gD’s role in penetration. C enhanced the activity of almost
all of the gB and gC MAb, but not the gD MAb. The
conformational change of HHV-1 gD when it binds
receptor provides a new neutralization site (Lazear
et al., 2012).
Passive immunity Ab protected against fatal multi-
systemic BHV-1 disease in newborn calves (Turin et al.,
1999), but did not prevent initial viral replication, result-
ing in latency. This results in seronegative latent carrier
(SNLC) animals after the maternal Ab declines (Lemaire
et al., 2000a; Nandi et al., 2009). Experimental passive
transfer of Ab did not protect completely, although
it prevented death from challenge (Marshall and
Letchworth, 1988).
aHV evade neutralizing Ab using three mechanisms
(Favoreel et al., 2006): (1) Fc receptor Ab binding (by
gE/gI, which is not apparent for BHV-1) (Whitbeck et al.,
1996); (2) endocytosis of GPs, or Ag-Ab complex inter-
nalization by same mechanism; and (3) hiding from Abs
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through intracellular retention of viral proteins and
directed egress to intimate cell–cell contacts. The synapse
can be seen as an example of the latter (Favoreel et al.,
2006). In HHV-1, cell-to-cell transmission depends on
gE–gI, which binds to components of cell junctions (while
gD localizes to apical surface) (Dingwell and Johnson,
1998). BHV-1 gC includes Ig-related domains. The low
gC reactivity of bovine antisera may be explained by
molecular mimicry (Fitzpatrick et al., 1989, 1990). Finally,
syncytial strains of HHV-1 avoid neutralization by not
using extracellular virus to infect neighboring cells. This
was stated to not occur with wild-type viruses, however
(Roizman et al., 2007).
2.2.11. Ab-dependent cell-mediated cytotoxicity
Ab binding to determinants on virus-infected cells may
lead to those cells being killed in a non-MHC restricted
manner. PMNs are the most effective mediators of ADCC.
Mfs also contribute, and LCs do not (Rouse et al., 1976;
Grewal et al., 1977). IFN and C enhance the activity
(Rouse and Babiuk, 1977). IgM is inactive in ADCC alone,
but can enable ADCC-C-mediated lysis, which may be
important early in the humoral response. BHV-1 infection
of Mfs limits their ability to perform ADCC (Ohmann and
Babiuk, 1986). The Fcg R of HHV-1 blocked ADCC
(Lubinski et al., 2011).
2.2.12. Other Ab activities
Ab label Ag on virions and virus-infected cells for activity
by C, phagocytes, and NK cells (Favoreel et al., 2006). Ab
to viral Ag can trigger the classic pathway of C activation
on virions and infected cells. It is not believed this is
important early in infection because high amounts of each
were needed for activity in vitro (Babiuk et al., 1975;
Rouse and Babiuk, 1977). Cattle have differences from
humans and mice in their FcR (particularly Fcg 2R),
possibly because of the different role of IgG re: mucosal
surfaces (Kacskovics, 2004). NK and other immune cells
bear FcR. Ab can also neutralize the immunosuppressive
effects induced by BHV-1 against T cells (Hutchings et al.,
1990).
The BHV-1 evasion methods for these activities would
be the same or similar to those cited for neutralization or
innate C activation (Muylkens et al., 2007), including viral
FcR and C3bR. Fc receptors, when present on aHV, can
serve to shield the Ag with normal Ig, or result in Ig
bridging (Ag–Ab–Fc) to prevent C activation. SHV1-
infected cells can shed or internalize Ab–Ag–C complexes
(Favoreel et al., 2003).
2.3. Other immune response considerations
2.3.1. Immune response in latency and reactivation
The role of the immune system in preventing reactivation
from latency is controversial. There is a chronic inflam-
matory (immune) response in latently infected TGs, with
elevated CD8+ and cytokine/chemokine expression. This
was interpreted as maintaining viral latency and suppres-
sing reactivation of HHV-1 (Theil et al., 2003). This role in
control of reactivation from latency in aHVs was noted
and believed potentially due to viral protein expression in
rare cells in the TG (Jones and Chowdhury, 2007). This
has been called ‘spontaneous molecular reactivation’.
IFN-g was also believed to play a role (Jones, 2003).
However, it has been reported that the latency associated
transcript (LAT) of HHV-1 is responsible for CD8+ CTL
functional exhaustion in TGs (Chentoufi et al., 2011).
Also, CD8+ T cells surround only a small proportion of
LAT+ neurons, but micro RNA (miRNA) are present in all
of the LAT+ cells (Held et al., 2011).
2.3.2. Mucosal immunity
The selective localization of mucosal LC to specific tissues
is due to their expression of chemokine receptors and the
differential expression of cognate chemokines and tissue-
specific addressins by epithelial cells (Czerkinsky and
Holmgren, 2012). T cells (CD4+ and CD8+) primed by DCs
in the local LN are influenced to home, based on re-
ceptors (Ciabattini et al., 2011). The chemokine/chemo-
kine receptor pairs CCL25/CCR9 and CCL28/CCR10 have
been shown to be important to trafficking of Ab-secreting
cells to mucosal tissues. The expression of these mol-
ecules is different in cattle than in humans and mice,
suggesting different mechanisms for accumulation in
specific mucosal tissues (Distelhorst et al., 2010).
2.3.3. Consequences of BHV-1 immunosuppression
The impact of BHV-1-encoded immunosuppression
factors on the outcome of the virus infection is clear, but
there may also be impacts on other infections. The con-
tribution of BHV-1 infection to ‘shipping fever’ (and
BRDC), indicated in the field by co-infections (Martin
et al., 1980) and demonstrated experimentally (Jericho
and Langford, 1978), is complex, but is believed to
include the immune and inflammatory response to BHV-1
(Hodgins et al., 2002; Ellis, 2009) as well as immunosup-
pressive effects previously cited in this review and
elsewhere (Levings and Roth, 2013) for multiple aspects
of the bovine immune response to BHV-1. Reduced
immune functions associated with anti-bacterial activities
were described in BHV-1 infection. They include im-
paired function of alveolar Mf (Fc and C receptor activity,
phagocytosis, PMN chemotaxis and respiratory burst),
and LC (proliferation, cytotoxicity), with reduction of IL-2
levels (Forman et al., 1982; Filion et al., 1983; McGuire
and Babiuk, 1984; Ohmann and Babiuk, 1985; Tikoo
et al., 1995a; Roth and Perino, 1998).
Some experiments have measured specific immuno-
suppressive effects relative to secondary bacteria. BHV-1
infection depressed LC blastogenic responses to
Mannheimia haemolytica and Pasteurella multocida and
delayed the anti-M. haemolytica Ab response. The PMN
infiltration of P. multocida-infected lungs was reduced,
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although the antibacterial activity of PMNs was not
significantly affected (Filion et al., 1983; McGuire and
Babiuk, 1984). It could be expected that any of the
non-agent-specific immunosuppressive effects of BHV-1
infection described would facilitate secondary infection,
including: inhibition of IFN signaling; chemokine or
C3b (or Ab) binding; and infection, function depression,
and/or killing of Mfs, PMNs, APCs, and T cells.
3. Vaccination
3.1. General BHV-1 vaccinology
Nucleosidic antiviral drugs have been used to treat human
herpesviral infections since the 1970s, and have been
tested and applied for limited applications in veterinary
species, including for HV infections (Rollinson et al.,
1988; Wilkins et al., 2003; van der Meulen et al., 2006;
Henninger et al., 2007). However, widespread clinical use
of antiviral drugs is not common in veterinary medicine
(Kahn et al., 2005). Administration of IFN (Cummins et al.,
1993) or IFN inducers (Theil et al., 1971) to reduce the
clinical signs of BHV-1 infection has been limited to
experimental trials. Anti-herpesviral immunomodulators
such as host defense proteins (Jenssen, 2009), double-
negative ‘intracellular immunization’ (Mu¨hlbach et al.,
2009), and gene therapy (Chase et al., 1990; Bunnell and
Morgan, 1998) are not currently used in food animal medi-
cine. Rather, biosecurity and vaccination are the primary
control measures for the diseases caused by BHV-1.
BHV-1 is a good candidate for conventional and
new vaccines (van Drunen Littel-van den Hurk, 2006).
Although there are subtypes of BHV-1 (Metzler et al.,
1985), the subtypes are broadly immunologically cross-
reactive and there is limited antigenic variation within a
geographic region. Also, BHV-1 is a stable virus, has a
limited host range, and has a viremic phase (van Drunen
Littel-van den Hurk, 2006). In natural infection there is a
strong, long-lasting and well-balanced Th1/Th2 immune
response to protective Ags, possibly due to persistent
infection (Kaashoek et al., 1996a). There is also a sig-
nificant response to other viral proteins that can serve as
markers. BHV-1 is easily grown (rapidly, to high titers) in
cell cultures, facilitating production of many types of
BHV-1 vaccines.
Conventional modified live virus (MLV) and killed virus
(KV) BHV-1 vaccines have been used for many years
(Kendrick et al., 1957; Kolar et al., 1972). However,
problems due to the nature of the virus (e.g., MLV im-
munosuppression), vaccine technologies (KV efficacy), or
control program needs (vaccine markers) encouraged the
use of new technologies to develop ‘second generation
veterinary viral vaccines’ (reviewed in Meeusen et al.,
2007; Zhao and Xi, 2011). The emphasis has been on
delivery of major GPs, and on use of major or minor GPs
as negative markers (Babiuk et al., 1996; Baranowski
et al., 1996; Turin et al., 1999). The goal of vaccination is a
well-balanced immune response, similar to that of
protection due to natural infection.
There is such a wide variety of BHV-1 vaccines
(in practice and particularly in the literature), that it can
be helpful to describe them as belonging to categories.
The most common divisions are: conventional and
molecular; replicating and non-replicating; and marker
and non-marker. Vaccines can also be categorized by
route (intranasal [IN], intramuscular [IM], etc.) or admin-
istration technique (e.g., aerosol, injection, ‘gene gun’).
The divisions are not absolute; e.g., some molecular vec-
tors (e.g., canarypox in mammals or alphavirus replicons)
do not replicate in the host but non-productively infect
cells and express Ag on the cell surface similar to live
vaccines (Taylor et al., 1995; Vander Veen et al., 2012).
Further, in some cases vaccines may be best used in
combination regimens, called ‘prime-boost,’ e.g., MLV
and KV gene-deleted vaccines (Muylkens et al., 2007), or
DNA and subunit vaccines (van Drunen Littel-van den
Hurk et al., 2008).
The ‘differentiating infected from vaccinated animals’
(DIVA) strategy (van Oirschot, 1999) usually employs a
vaccine that is missing an antigenic marker, or a positive
marker can also be added (Chowdhury, 1996), combined
with a complementary diagnostic assay for that marker. A
diagnostic assay for protective vaccine Ag that is present
in both the vaccine and field virus is also employed.
Marker vaccines can range from a live virus with a mu-
tation or deletion in a single gene to single glycoprotein
subunit vaccines. A desirable negative marker protein is
one that is not needed for in vitro production, not critical
for protection, present in all wild-type viruses, and that
induces a rapid, strong, long-lasting response in both
nai¨ve and vaccinated animals (Kaashoek et al., 1996b; van
Drunen Littel-van den Hurk, 2006). Also, the companion
diagnostic should be sensitive and specific. Widely em-
ployed BHV-1 marker companion diagnostics have
occasionally demonstrated problems with each of these
characteristics (van Oirschot et al., 1999; Muylkens et al.,
2007).
The extensive research on BHV-1 and the bovine
immune response to it has resulted in reports on a wide
variety of experimental vaccines in the literature. Many of
them are briefly described below. However, the currently
licensed vaccines in the US and EU include only MLV and
KV vaccines of cell culture passaged virus, gE-deleted
virus, or temperature sensitive (ts) mutant virus, adminis-
tered IM, subcutaneously, or IN.
3.2. Non-replicating vaccines
3.2.1. Killed virus
Conventional KV vaccines have been used for decades
(Kolar et al., 1972). They have the advantage of safety,
including in pregnant cattle. However, typically two
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immunizations are needed, the immune response is
primarily humoral, and the duration of immunity is
shorter than for MLV vaccines (Tikoo et al., 1995a; van
Drunen Littel-van den Hurk, 2007). The adjuvants
commonly added to increase immunogenicity can intro-
duce problems of their own (Spickler and Roth, 2003).
The conventional KV BHV-1 vaccine is produced
through physicochemical inactivation of infected cell
culture fluids. Agents used have included formalin, beta-
propiolactone, binary ethylene amine, ethanol, UV
irradiation, and heat (Haralambiev, 1976; Levings et al.,
1984; van Drunen Littel-van den Hurk, 2006). The vaccine
includes all components of the virus (and cell culture),
but there is the concern that inactivation could damage
key epitopes (Jones and Chowdhury, 2007). A marker
vaccine can be produced using the same inactivation
methods when the production virus is gene-deleted (e.g.,
gE-) (Kaashoek et al., 1995; Strube et al., 1996).
3.2.2. Subunit
Subunit vaccines containing the major GPs (gB, gC, gD)
have proven effective. These included detergent extracts
of virus preparations to solubilize envelope GPs (Lupton
and Reed, 1980), including incorporation of the extracts
into immune stimulating complexes (ISCOMs) (Trudel
et al., 1988). Individual GPs have also been purified from
such extracts for vaccine use using affinity chromato-
graphy (Babiuk et al., 1987). gB, gC, and gD subunit
vaccines were each protective, with gD eliciting the
highest Ab titers and best protection (Babiuk et al., 1987).
The GPs for subunit vaccine use have also been pro-
duced using various expression systems. Vaccinia and
adenovirus systems in mammalian cells, and baculovirus
systems in insect cells yielded protective GPs due to their
glycosylation. Escherichia coli systems produced partial
protection (van Drunen Littel-van den Hurk et al., 1993).
A truncated, secreted version of gD was produced in a
bovine cell line (Kowalski et al., 1993) and shown
protective (van Drunen Littel-van den Hurk et al., 1994).
When the adjuvant CpG was incorporated into the vac-
cine, no virus was shed after challenge (Ioannou et al.,
2002).
3.2.3. Anti-idiotype
Anti-idiotype (anti-Id or Ab2) immunizations for HV
(Kennedy et al., 1984; Gurish et al., 1988; Tsuda et al.,
1992; Zhou and Afshar, 1995), and BHV-1 in particular
have been reported. Srikumaran et al. (1990), Hariharan
et al. (1991), and Orten et al. (1991) used neutralizing
murine MAb as Ab1 to generate bovine polyclonal Ab
(PAb), bovine MAb, or rabbit PAb Ab2 respectively,
which in turn were used to elicit neutralizing Ab3 in mice.
Orten et al. (1993) immunized calves with an Ab2 (rabbit
PAb anti-Id to murine anti-gB and gD MAb), resulting in a
slight reduction of clinical signs and one calf producing
BHV-1-neutralizing antibodies.
3.3. Replicating vaccines
3.3.1. Modified live (attenuated) virus
MLV vaccines have been used for BHV-1 disease since
1956 (Kendrick et al., 1957). MLV in general are generated
by passage in cell culture, sometimes in heterologous cell
culture (Quinlivan et al., 2011). This allows for mutations
or deletions in genes important to viral fitness, but that are
not essential to in vitro replication. The main advantage
of MLV is that they replicate in the host’s target cells, so Ag
is presented on MHC I (eliciting CTLs), as well as on MHC
II (eliciting humoral immunity) (van Drunen Littel-
van den Hurk, 2007). After one dose of MLV, when PBLs
were exposed to live BHV-1, CD25 was increased in
CD4+, CD8+, and g d T cells (Endsley et al., 2002). BHV-1
MLVs also typically elicit substantial duration of immunity
(van Drunen Littel-van den Hurk, 2007).
BHV-1 conventional MLV problems have included
those specific to BHV-1 disease. These include virulence
(e.g., in small calves or pregnant animals) (Whetstone
et al., 1986; Bryan et al., 1994; Jones and Chowdhury,
2007; O’Toole et al., 2012), latency (Pastoret et al., 1980;
Whetstone et al., 1986), and immunosuppression, includ-
ing a reduction in the response to another vaccine ad-
ministered simultaneously (Harland et al., 1992). Other
problems common to all MLVs can also occur. These
include reversion to virulence (Belknap et al., 1999), lack
of efficacy due to overattenuation, and adventitious
agents. The latter is particularly likely if the vaccine is
produced in host cells or with host ingredients (Wessman
and Levings, 1999; Falcone et al., 2003), but can occur
even if the vaccine is produced with non-host cells or
ingredients (Wilbur et al., 1994). A ts MLV was generated
using chemical mutagenesis (Tikoo et al., 1995a), which
was safe for pregnant animals.
3.3.2. Gene deleted
Although gene mutations and deletions may occur using
conventional attenuation (Kaashoek et al., 1994), their
design can be more controlled with genetic engineering.
There are typically two goals in constructing gene-deleted
live vaccines: (1) remove/reduce virulence or another
undesirable disease trait; and/or (2) remove (or add) a
marker detected by a companion diagnostic, usually a
serologic marker, which can also be detected on a viral
isolate. In the case of BHV-1, deletions in the thymidine
kinase, gC, gE, gG, gI, Us9, LR, and UL49.5 genes have
been made to reduce virulence (Kit et al., 1985;
Chowdhury, 1996; Kaashoek et al., 1998), recrudescence
(Kaashoek et al., 1998; Inman et al., 2001), and/or im-
munosuppression (Wei et al., 2012). Viral envelope GPs
have been targeted for serologic markers, including gC
and gE due to the host’s strong serologic responses to
these non-essential proteins.
Disadvantages of gene-deleted live vaccines are under-
or over-attenuation (Kaashoek et al., 1998), depending on
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the genes chosen. Since virulent isolates are usually the
starting material for deletion work, recombination can
also be an issue (reviewed in Thiry et al., 2005). BHV-1
recombination in vivo between two gene-deleted strains
was demonstrated, which led to wild-type virus (Schynts
et al., 2003). In addition, recombination leading to a
virulent marker (gE) BHV-1 virus was shown (Muylkens
et al., 2006a, b), a situation that could confuse eradication
campaigns. Such recombination of gene-deleted vaccines
has been demonstrated for other aHVs (Henderson et al.,
1991; Lee et al., 2012).
3.3.3. Live virus vectored
Vaccination using live vectors for BHV-1 GPs has elicited
VN Ab, CMI responses, and/or partial protection.
These have included vaccinia-vectored gB and gC (VN,
van Drunen Littel-van den Hurk et al., 1989), bovine
adenovirus 3 expressing gD (VN and CMI, Zakhartchouk
et al., 1999), human adenovirus 3 or 5 expressing gC or
gD (VN, Gupta et al., 2001), and Newcastle disease virus-
vectored gD (partial protection, Khattar et al., 2010).
Although an aHV chimeric veterinary vaccine has been
developed (Cochran et al., 2000, 2001), no chimeric BHV-
1 vaccine has been reported.
3.3.4. DNA vaccines
DNA vaccines for BHV-1 have also been used in trials.
DNA vaccines provide certain advantages over con-
ventional MLV, including safety, stability, and efficacy in
the presence of maternal antibodies (Donnelly et al.,
1997). They result in Ag presentation by both MHC I and
II, similar to live vaccines (Gurunathan et al., 2000),
although they typically elicit a Th1 response. Although
replicating, they can be made specific to one or a few Ag.
A disadvantage at this time is their mode of delivery, e.g.,
veterinary use of the gene gun is not currently practical
(Loehr et al., 2001). In most reported trials, complete
protection was not achieved.
BHV-1 GP (gB, gC, and gD) DNA has been adminis-
tered by a variety of routes. Trials include gB, gC, and gD
individually (Cox et al., 1993), gD (van Drunen Littel-
van den Hurk et al., 1998), gC with ubiquitin (Gupta
et al., 2001), secreted gD (Castrucci et al., 2004), a com-
bined, secreted gB–gD, (Caselli et al., 2005), gB (Huang
et al., 2005), and gD with CpG (van Drunen Littel-van den
Hurk et al., 2008).
3.3.5. BHV-1 as a vector
The use of BHV-1 as a vector of other proteins has a
variety of advantages, including knowledge of the
molecular biology of BHV-1, existing systems for vaccine
production, and the already-widespread use of BHV-1
vaccines (so there are few or no new safety or
serosurveillance concerns) (Jones and Chowdhury,
2007). The virus has been used to express IL-1b (Raggo
et al., 1996), IL-2, IL-4 (Ku¨hnle et al., 1996), IFN-g (Raggo
et al., 2000), and to display IFN-a (Keil et al., 2010).
Expression of cytokines could provide an adjuvant effect
for BHV-1 vaccination. Protective immunogens of other
bovine viruses have been expressed in BHV-1. An FMDV
VP1 epitope was inserted as the N-terminal sequence of a
BHV-1 gC fusion protein, was expressed on the surface of
virions and infected cells, and elicited protective levels of
Ab to FMD, while protecting against BHV-1 (Kit et al.,
1991). The G protein of bovine respiratory syncytial virus
(BRSV) was expressed in BHV-1 and the vaccine provided
the same degree of protection to BHV-1 and BRSV in
calves as a multivalent vaccine (Schrijver et al., 1997).
Bovine viral diarrhea (BVD) virus E2 protein was
expressed in BHV-1 (Cochran, 1998) and the vaccine
virus elicited VN Ab to BVD (Kweon et al., 1999).
Parainfluenza 3 fusion (F) and hemagglutinin (HN) genes
were inserted into BHV-1 (Haanes and Wardley, 1997;
Cochran, 1998). In addition, insertion of an influenza
hemagglutinin 1 (HA1) sequence resulted in HA1 being
expressed with gG as a fusion protein on the outside of
virions and infected cells (Keil et al., 2010). aHV have
also been proposed for use with other viruses as chimeric
vectors (Epstein and Manservigi, 2004) and as episomal
systems for gene therapy (Macnab et al., 2008).
3.4. Routes
BHV-1 infects via mucosal epithelium, so stimulating im-
munity for those surfaces would be desirable. However,
most of the conventional vaccines are parenterally ad-
ministered and may result in systemic rather than mucosal
immunity. In contrast, mucosal immunization is said
to induce mucosal as well as systemic immunity (Loehr
et al., 2000). Immunization of mucosal surfaces results in
good Ag detection, and B and T cells stimulated in the
mucosa home to mucosa in general and to the immunized
mucosal tissue specifically (Neutra and Kozlowski, 2006).
A variety of mucosal routes have been employed or
suggested for viral vaccines (including aHV), such as oral,
nasal, vaginal, ocular, sublingual, and anorectal (Shiau
et al., 2001; Czerkinsky and Holmgren, 2012; Pavot et al.,
2012).
A ts BHV-1 vaccine administered IN was shown to
induce secretory IgA and a CMI response (Frerichs et al.,
1982). Israel et al. (1992) demonstrated mucosal immunity
to BHV-1 subunit vaccine using cholera B subunit as an
adjuvant and the IN route. A regime using a conventional
BHV-1 IN vaccine was shown to confer rapid protection
(Roth and Carter, 2000; Endsley et al., 2002). Intravaginal
vaccination with gD DNA (Loehr et al., 2000, 2001)
protected against IN BHV-1 challenge. Oral vaccination
with BHV-1 in utero stimulated mucosal immunity
(Gerdts et al., 2002). A gD DNA vaccine was administered
IN with reduction in challenge virus shedding (Castrucci
et al., 2004), and a gB DNA vaccine administered vulvo-
vaginally elicited partial protection from genital lesions
(Huang et al., 2005).
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3.5. Application
The ultimate goal of BHV-1 vaccination would be to
prevent infections, which can in turn lead to latency/
recrudescence and spread. Although this may occasion-
ally be achieved (Israel et al., 1992), it is not routinely
practical.
A challenge for vaccination in cattle is immunizing
stressed animals, because vaccines are often administered
in association with movement and other treatments. Such
stressors impact immune function (Kelley, 1980) and have
been demonstrated to be associated with increased blood
cortisol levels. High cortisol levels can impair phagocytic
cell function, decrease CMI, and decrease Ab response to
primary vaccination (Roth and Perino, 1998). Vaccinating
young animals includes the difficulty of vaccinating in the
face of passive immunity (Menanteau-Horta et al., 1985),
and young animals may mount poor Th1 responses (van
Drunen Littel-van den Hurk, 2006). Use of CpG adjuvants
or DNA vaccines may help with the younger animal
immunization.
In the United States, BHV-1 vaccines are currently used
as an aid in the prevention of disease. Between 150 and
200 million doses are produced annually (Anon, 2011b;
personal communication), all of the conventional types
(MLV and KV). In some countries of the EU, (gE) marker
vaccines (live and KV) are used in eradication programs
(van Oirschot et al., 1996; Kahrs, 2001; Ackermann and
Engels, 2006; van Drunen Littel-van den Hurk, 2006). As
vaccines cannot prevent infection, vaccination must be
frequent to keep recrudescence low, and culling based on
DIVA serology employed. A significant issue for control
and eradication is SNLC cattle that can re-excrete after a
stress (Hage et al., 1998). It has been shown that young
animals can remain seronegative when infected while pro-
tected from disease by passive immunity, and that these
infections can recrudesce at a later time, resulting in SNLC
animals (Lemaire et al., 1995, 2000a, b).
4. Summary/conclusions
In summary, there is a delicate balance between viral
infection, host response, and viral evasive measures in
BHV-1 infection and immunity in cattle. BHV-1 has a
rapid life cycle and robust systems for entry, transcription,
assembly and egress. The host responds with multiple
tools, from infected-cell IFN to Ab-assisted infected cell
killing. Like all aHV, BHV-1 has multiple evasion stra-
tegies to blunt or delay the host response, including in
some cases multiple measures for the same host effector
mechanism. The timing of response vs. viral replication
(and spread in the animal and between animals) is there-
fore critical for disease outcomes. Maternal Ab provides
humoral tools from the dam’s immune response, and
vaccination ensures the response to infection will be a
rapid, strong secondary immune response that can pro-
vide the host with the advantage needed to prevent
severe disease on primary infection.
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